We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
IQVIA posted 6% organic growth in Q2'26, with R&DS up 7% and commercial revenues rising 5%.
IQVIA's R&DS bookings rose 19.3%, while backlog reached $34.2 billion at the end of June 2026.
IQV had deployed 294 AI agents across 90 use cases, with broad adoption among top pharma companies.
IQVIA (IQV - Free Report) stock has surged 60.1% in the past six months. The company’s shares outpaced the industry’s 4.1% return and the Zacks S&P 500 Composite's 14% rally.
6-Month Share Price Performance
Image Source: Zacks Investment Research
Let us delve deeper into the factors that have contributed to the company’s outperformance.
Accelerating Organic Growth
IQVIA signals improving demand for its core business, as evidenced by 6% organic year-over-year growth in the second quarter of 2026. Both the clinical and commercial sides of the company have provided significant impetus to organic growth. Research & Development Solutions (R&DS) delivered organic growth of 7%, demonstrating strength in full-service bookings, translating into a quarterly book-to-bill ratio of 1.22.
The commercial side delivered a 5% year-over-year organic revenue rise, driven by newly approved product launches and expanded breadth of services utilized by the company. Banking on these positives, management appears fairly optimistic, expecting to incorporate nearly 100 basis points higher organic revenue growth during 2026 compared with its previous expectations.
Solid R&DS Bookings & Backlog
The company’s R&DS business is supported by strengthening demand and enhanced booking trends. In the second quarter of 2026, its net new bookings escalated 19.3% year over year, resulting in a book-to-bill ratio of 1.22.
Backlog stood at $34.2 billion at the end of June 2026, while revenues expected to convert from backlog over the next 12 months exceeded $9 billion, a 7.5% year-over-year uptick. This trajectory demonstrates improving demand visibility and support expectations for sustained top-line growth, mainly as strong bookings convert into revenues over future periods.
Rapid AI Adoption Strengthens Competitive Position
IQV’s rising AI adoption is strengthening its competitive position and supporting business growth. The company had deployed 294 AI agents across 90 use cases by the second quarter of 2026. This highlights the expanding scale of its agentic AI capabilities. Out of the top 20 pharma companies, 19 had already deployed the company’s solutions in their workflows, highlighting broad customer adoption.
Four of the top 10 pharma companies contracted with the company to co-develop AI solutions. These capabilities aid IQVIA in differentiating its offerings across clinical and commercial business and enhance win rates.
Rapid AI adoption can improve customer relationships, expand business opportunities and support persistent revenue growth, bolstering investor morale in the company’s growth outlook.
BrightSpring Health Services has a long-term earnings growth expectation of 47%. BTSG delivered a trailing four-quarter earnings surprise of 16.1%, on average.
Centene has a long-term earnings growth expectation of 32.4%. CNC delivered a trailing four-quarter earnings surprise of 151.3%, on average.
View the Zacks #1 Rank List
Image: Bigstock
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
Key Takeaways
IQVIA (IQV - Free Report) stock has surged 60.1% in the past six months. The company’s shares outpaced the industry’s 4.1% return and the Zacks S&P 500 Composite's 14% rally.
6-Month Share Price Performance
Let us delve deeper into the factors that have contributed to the company’s outperformance.
Accelerating Organic Growth
IQVIA signals improving demand for its core business, as evidenced by 6% organic year-over-year growth in the second quarter of 2026. Both the clinical and commercial sides of the company have provided significant impetus to organic growth. Research & Development Solutions (R&DS) delivered organic growth of 7%, demonstrating strength in full-service bookings, translating into a quarterly book-to-bill ratio of 1.22.
The commercial side delivered a 5% year-over-year organic revenue rise, driven by newly approved product launches and expanded breadth of services utilized by the company. Banking on these positives, management appears fairly optimistic, expecting to incorporate nearly 100 basis points higher organic revenue growth during 2026 compared with its previous expectations.
Solid R&DS Bookings & Backlog
The company’s R&DS business is supported by strengthening demand and enhanced booking trends. In the second quarter of 2026, its net new bookings escalated 19.3% year over year, resulting in a book-to-bill ratio of 1.22.
Backlog stood at $34.2 billion at the end of June 2026, while revenues expected to convert from backlog over the next 12 months exceeded $9 billion, a 7.5% year-over-year uptick. This trajectory demonstrates improving demand visibility and support expectations for sustained top-line growth, mainly as strong bookings convert into revenues over future periods.
Rapid AI Adoption Strengthens Competitive Position
IQV’s rising AI adoption is strengthening its competitive position and supporting business growth. The company had deployed 294 AI agents across 90 use cases by the second quarter of 2026. This highlights the expanding scale of its agentic AI capabilities. Out of the top 20 pharma companies, 19 had already deployed the company’s solutions in their workflows, highlighting broad customer adoption.
Four of the top 10 pharma companies contracted with the company to co-develop AI solutions. These capabilities aid IQVIA in differentiating its offerings across clinical and commercial business and enhance win rates.
Rapid AI adoption can improve customer relationships, expand business opportunities and support persistent revenue growth, bolstering investor morale in the company’s growth outlook.
Zacks Rank & Stocks to Consider
IQV currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader Zacks Medical sector are BrightSpring Health Services (BTSG - Free Report) and Centene (CNC - Free Report) . These two companies presently flaunt a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health Services has a long-term earnings growth expectation of 47%. BTSG delivered a trailing four-quarter earnings surprise of 16.1%, on average.
Centene has a long-term earnings growth expectation of 32.4%. CNC delivered a trailing four-quarter earnings surprise of 151.3%, on average.